DRUG STUDY

SIDE EFFECTS/
NAME OF ROUTE, DOSAGE AND MECHANISM INDICATION CONTRAINDICATION NURSING
DRUG FREQUENCY OF ACTION ADVERSE EFFECTS CONSIDERATIONS
Generic Name: Angina: Binds with opioid Relief of Contraindications: Possible Side Effects: – Observe the patient’s 10
Morphine PO (Immediate-Release): receptors within moderate to All Formulations: rights of medication
Ambulatory pts, pts not
(Sulphate) Adults, Elderly: 10–30 mg CNS, inhibiting severe, acute, or Hypersensitivity to administration
in severe pain may
q4h as needed. (Solution): ascending pain chronic pain; morphine. Acute or severe
Brand Name: 10– 20 mg q4h as needed. pathways. analgesia during asthma, GI obstruction, experience nausea, Baseline Assessment:
vomiting more
Duramorph, (Tablet): 15–30 mg q4h as labor, pain due to known or suspected – Pt should be in recumbent
frequently than pts in
Infumorph, needed. Therapeutic MI, dyspnea from paralytic ileus, severe position before drug is
supine position or who
Roxanol Children 6 Months of Age Effect: Alters pulmonary edema hepatic/renal impairment, given by parenteral route.
have severe pain
and Older Weighing 50 kg or pain perception, not resulting from severe respiratory – Assess onset, type, location,
Classification: Greater: emotional chemical depression. duration of pain.
Frequent:
Pharmaco- 15–20 mg q3–4h as needed. response to pain. respiratory irritant. – Obtain vital signs before
– Sedation
therapeutic: Children 6 Months of Age Extended-Release: giving medication. If
– Decreased B/P
Infumorph: Use GI obstruction, acute respirations are 12/min or
OO pp ii oo ii dd aanndd OOllddeerr (including orthostatic
in devices for
WWeeiigghhiinngg LLeessss
This website stores data such as mintarnaacgtainbgl less (20/min or less
hpyopsteorpcearabtiave hypotension) in children),
aacookies
((SSggccooto
hhenable
nneeiissddessential site
ttuullee IIII)).. pain, – Diaphoresis withhold
e chronic pain.
TTwell – Facial flushing medication, contact
functionality, 00as ..hh22asaa––marketing,
Extended-release: Injection: – Constipation physician.
personalization,
nn00..and analytics.
555500 mmkkggg You HF due to lung disease; – Dizziness – Effect of medication is
Use only when
may change gyour settings
//kk:: gg qq33––44hh at
aass any time repeated doses for arrhythmias, head injury, – Drowsiness reduced if full pain
seizures, acute alcoholism. recurs before next dose.
or accept thenneeeeddeedd..
default settings. extended periods of – Nausea
CC ll ii nn ii cc aa ll :: CChhiillddrreenn time are required Labor when premature – Vomiting.
around the clock. birth expected. Increased Intervention:
YYoouunnggeerr TThhaann 66
OO pp ii oo ii dd MMoonntthhss:: intracranial pressure – Monitor vital signs 5–10 min
Occasional:
Privacy Policy
aannaallggeessiicc.. ((OOrraall ssoolluuttiioonn))::
– Allergic reaction
after IV administration, 15–
00..0088––00..11 Immediate-Release: 30 min after SQ, IM.
mmgg//kkgg qq33––44hh aass Hypercarbia (rash, pruritus) – Be alert for decreased
Marketing
nneeeeddeedd – Dyspnea respirations, B/P.
Extreme Cautions: – Confusion – Check for adequate voiding.
Personalization
PPOO ((EExxtteennddeedd-- COPD, cor pulmonale, – Palpitations – Monitor daily pattern of
RReelleeaassee)):: hypoxia, hypercapnia, – Tremors bowel activity, stool
Analytics
AAdduullttss,, preexisting respiratory – Urinary retention consistency; avoid
EEllddeerrllyy:: depression, head injury, – Abdominal cramps constipation.
DDoossaaggee increased ICP, severe – Initiate deep breathing,
– Vision changes
Save r r ee qq Accept All
uu iirr ee hypotension. – Dry mouth coughing exercises,
e e ss ttaa bb llii ss particularly in those
mm ee nntt ss hh Cautions: with
hhee dd uu ss iinn
 Adults, Elderly: 2.5–5 mg q3–
Biliary tract disease, – Headache pulmonary impairment.
4h as needed. Note: Repeated
pancreatitis, Addison’s – Decreased appetite – Assess for clinical
doses (e.g., 1–2 mg) may be
disease, cardiovascular – Pain/burning at improvement; record onset of
given more frequently (e.g.,
disease, morbid obesity, injection site pain relief.
every hr) if needed. Children
adrenal insufficiency, – Consult physician if pain
50 kg or Greater:
elderly, hypothyroidism, Rare: relief is not adequate.
Initially, 2–5 mg q2–4h as
urethral stricture, prostatic –
needed.
hyperplasia, debilitated Paralytic ileus Patient/Family Teaching:
Children Weighing Less
pts, pts with CNS Adverse effect: – Discomfort may occur with
Than 50 kg:
depression, toxic – Overdose results in: injection.
Initially, 0.05 mg/kg. Range:
psychosis, seizure O
– Change positions slowly to
0.1–0.2 mg/kg q2– 4h as Respiratory
disorders, alcoholism. avoid orthostatic
needed. Neonates: Initially, depression
0.05–0.1 mg/kg/dose q4–6h as hypotension.
O Skeletal muscle
needed. – Avoid tasks that require
flaccidity alertness, motor skills until
O Cold/ clammy skin
response to drug is
This websiteIIVV CCoonnttiinnuuoouuss
stores data such as
IInnffuussiioonn:: O Cyanosis
established.
cookies to enable essential site
AAdduullttss,, O Extreme – Avoid alcohol, CNS
functionality, as well as marketing,
EEllddeerrllyy:: 00..88––1100 drowsiness depressants.
mmgg//hhrr.. RRaannggee:: progressing to – Tolerance, dependence may
personalization, and analytics. You
TTiittrraattee uupp ttoo 8800 seizures occur with prolonged use
may change mmgg//hhrr..
your settings at any time O

Stupor of high doses.

CChhiillddrreenn
or accept the default settings. O – Report ineffective pain
WWeeiigghhiinngg 5500 kkgg Coma control, constipation,
oorr GG rr ee aa tt ee rr :: – Tolerance to urinary retention.
11..55 mmgg//hhrr.. analgesic effect
CChhiillddrreenn
Privacy Policy (Physical dependence
WWeeiigghhiinngg LLeessss may occur with
TThhaann 5500 KKgg::
Marketing
IInniittiiaallllyy,, 00..0011 – rPerpoeloantegdedusd
mmgg//kkgg//hhrr..
eu) ration of action,
Personalization
RR aa nn
((11 00 ––gg44ee00:: cumulative effect
may occur in those
Analytics
00 mm..00ccgg11//–– with hepatic/renal
kk00gg..00//hh44rrmm)).. impairment.
gg//kkgg//hhrr – Antidote: Naloxone
NNEEOONNAATTEESS::
Save Accept All
References:
Kizior, R. J. & Hodgson, K. J. (2019). Saunders Nursing Drug Handbook 2019. Elsevier Inc.

This website stores data such as

cookies to enable essential site
functionality, as well as marketing,
personalization, and analytics. You
may change your settings at any time
or accept the default settings.

Privacy Policy

Marketing

Personalization
Analytics

Save Accept All